Nanexa

1,87 SEK

+2,74 %

Mindre end 1K følgere

NANEXA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+2,74 %

+5,88 %

-21,67 %

-10,64 %

-13,33 %

-26,01 %

+7,71 %

-86,46 %

-77,12 %

Nanexa is a drug delivery company with a proprietary platform that is used for the formulation of injectable depot drugs that create a supply of drugs to the blood. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology, which encloses pharmaceutical particles with a thin shell and creates opportunities for pharmaceutical companies to develop new products. Nanexa has cooperation with several pharmaceutical companies, mainly around the Nordic market.

Markedsværdi

297,04 mio. SEK

Aktieomsætning

398,24 t SEK

Omsætning

24,36 mio.

EBIT %

-106,98 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

19.2

2026

Årsrapport '25

29.4

2026

Delårsrapport Q1'26

27.8

2026

Delårsrapport Q2'26

Alle

Selskabsmeddelelser

Eksterne analyser

ViserAlle indholdstyper

Eksterne analyser7.11.2025, 08.58

Nanexa: Intensified focus on deals amid growing funding pressure - Emergers

Nanexa’s Q3 report underscores a pivotal moment for the company. While interest in its PharmaShell technology remains strong, with advanced business discussions ongoing and an extended evaluation agreement in a multi-billion-dollar indication, the financial...

Pressemeddelelse7.11.2025, 07.00

Emergers: Equity Research | NANEXA: Intensified focus on deals amid growing funding pressure

Selskabsmeddelelse6.11.2025, 07.00

Nanexa publishes interim report for January-September 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Pressemeddelelse16.10.2025, 06.25

Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025

Selskabsmeddelelse1.10.2025, 10.40

Nanexa AB changes Certified Adviser to Tapper Partners AB

Pressemeddelelse22.9.2025, 06.00

Nanexa receives Japanese patent approval for specific PharmaShell structure

Eksterne analyser28.8.2025, 06.09

Nanexa: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Emergers

Nanexa presented strong validation of its PharmaShell technology during the first half of 2025, with Phase I data showing once-monthly liraglutide exposure over 36 days without significant gastrointestinal side effects. The company also gained industry...

Pressemeddelelse28.8.2025, 06.00

Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap

Selskabsmeddelelse27.8.2025, 05.00

Nanexa publishes interim report for January-June 2025

Pressemeddelelse8.8.2025, 08.43

Nanexa Signs Continuation of Feasibility Agreement with Major Pharmaceuticals Company to Investigate PharmaShell® Long-Acting Formulations in a Multi-Billion USD Market

Pressemeddelelse24.6.2025, 06.00

Presentation of NEX-22 phase I data: A once-monthly GLP-1 injection receives positive response at the 85th ADA Scientific Sessions in Chicago

Pressemeddelelse3.6.2025, 13.10

Nanexa Highlights NEX-22 and PharmaShell® During an Intensive Period of International Exposure

Pressemeddelelse23.5.2025, 07.15

All samples analyzed from the 30 mg dose group in the NEX-22 Phase I study

Selskabsmeddelelse15.5.2025, 13.45

Bulletin from Nanexa’s Annual General Meeting

Pressemeddelelse8.5.2025, 11.06

Nanexa Receives Approval for Late Breaking Abstract at ADA Congress in Chicago in June

Eksterne analyser7.5.2025, 07.23

Nanexa: Clinical milestones align ahead of phase Ib/II and licensing push - Emergers

Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 project, with preliminary PK data from the final dose cohort confirming a dose-dependent profile. Management now targets treatment of the first patient in ...

Pressemeddelelse7.5.2025, 06.00

Emergers: Equity Research | NANEXA: Clinical milestones align ahead of phase Ib/II and licensing push

Selskabsmeddelelse6.5.2025, 06.15

Nanexa publishes interim report for January-March 2025

Selskabsmeddelelse5.5.2025, 19.35

Nanexa and Applied Materials terminates collaboration

Pressemeddelelse5.5.2025, 09.55

Analysis of the first samples from the 30 mg dose group in the NEX-22 Phase I study shows continued promising results

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.